Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider – Nasdaq
Philadelphia Business Journal |
Gilead Drug Approval Fuels Interest in CAR–T Space: 3 Stocks to Consider
Nasdaq Interest in the CAR-T (chimeric antigen receptor T cells) space continues to build up with the FDA giving its nod to the second CAR-T therapy last week. Gilead Sciences's GILD Yescarta, a cell-based gene therapy, gained approval for the treatment of … 3 Gene Therapy Stocks That Could Make You Rich FDA approves 2nd gene therapy targeting non-Hodgkin lymphomas Kite's CAR T cell therapy Yescarta gets US FDA nod to treat adults with certain types of large B-cell lymphoma |
